Alastair Riddell

Alastair J.
Riddell currently works at Nemesis Biosciences Ltd., as Chairman from 2016, South West Peninsula AHSN Ltd., as Chairman from 2016, Cristal Delivery BV, as Member-Supervisory Board from 2015, and Small Pharma, Inc., as Chief Operating Officer from 2022.
Dr. Riddell also formerly worked at Stem Cell Sciences Plc, as Chief Executive Officer from 2007 to 2009, Pharmagene Plc, as Chief Executive Officer from 1998 to 2005, Paradigm Therapeutics Ltd., as Chief Executive Officer & Executive Director from 2005 to 2007, Bioseek UK Ltd., as Chief Executive Officer, Asset Realisation Co. Ltd., as Chief Executive Officer, Silence Therapeutics Plc, as Executive Chairman in 2015, Feedback Plc, as Non-Executive Chairman in 2019, Surface Therapeutics Ltd., as Chairman, PCT Shareholders Ltd., as Chairman, DefiniGEN Ltd., as Chairman from 2012 to 2016, Procure Therapeutics Ltd., as Chairman from 2009 to 2012, Nuformix Plc, as Executive Chairman from 2021 to 2022, Sareum Holdings Plc, as Director, CXR Biosciences Ltd., as Non-Executive Director, The Bioindustry Association, as Director, Sareum Ltd., as Non-Executive Director, Skyline Vet Pharma, Inc., as Director, and Entero Therapeutics, Inc., as Independent Director from 2015 to 2025.
Dr. Riddell received his undergraduate degree and doctorate degree from the University of Aston and graduate degree from the University of Birmingham School.